Oral administration therapy of isosorbide (ISOBIDE) for Meniere's disease: Methods of the medication in cases with different serum osmotic pressure

  • Tokumasu Koji
    Kitasato University, School of medicine, Department of Otorhinolaryngology
  • Naganuma Hideaki
    Kitasato University, School of medicine, Department of Otorhinolaryngology
  • Hashimoto Shin-ichiro
    Kitasato University, School of medicine, Department of Otorhinolaryngology
  • Ito Akihiko
    Kitasato University, School of medicine, Department of Otorhinolaryngology
  • Wada Masaoki
    Kitasato University, School of medicine, Department of Otorhinolaryngology
  • Okamoto Makito
    Kitasato University, School of medicine, Department of Otorhinolaryngology
  • Yamane Masaaki
    Toranomon Hospital, Department of Otorhinolaryngology

Bibliographic Information

Other Title
  • メニエール病のイソバイド療法:投与法の検討

Search this article

Abstract

Hyperosmotic solution of isosorbide has been used for treatment of Meniere's disease since Kitahara et al., Larsen et al. and Nozawa et al.. In recent studies reported that ADH is acting to open water channels, AQP-2 at the endlymphatic membrane and may act worse for labyrinthine hydrops. It is important the serum concentration of isosorbide after administration because ADH should be released if the serum osmotic pressure is elevated by isosorbide above more than 2% of normal serum osmotic pressure. In this study the equation predicting isosrbide serum concentration after oral administration was proposed on the basis of the data by Wakiya's report. It was confirmed the serum osmotic pressure remains below the threshold level for increasing ADH secretion by the routine method of 30 ml/once, 3 times every day. However, the method of 30 ml/once, single or two times every day should be recommended when the serum osmotic pressure before the medication is above 289 mOsm/kg.

Journal

  • Equilibrium Research

    Equilibrium Research 66 (2), 64-72, 2007

    Japan Society for Equilibrium Research

References(23)*help

See more

Details 詳細情報について

Report a problem

Back to top